Dr Reddy’s Earnings Surpass Estimates With Double-Digit Revenue Growth

Dr Reddy’s Laboratories posted consolidated revenue of ₹16,250 crore for the September quarter, up 10% year on year, while profit after tax rose 14% to ₹1,437 crore, exceeding analyst projections. The company benefited from strong North America formulations, new launches, and margin improvement from cost controls. Management reiterated guidance for continued product diversification and R&D-driven expansion. Brokerages maintained positive outlooks citing consistent free cash generation and balance-sheet strength supporting shareholder returns despite pricing headwinds in select markets.